Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/13605
Title: Plasmonic functional assay platform determines the therapeutic profile of cancer cells
Authors: Çetin, Arif E.
Topkaya, Seda Nur
Yazıcı, Ziya Ata
Yalçın Özuysal, Özden
Keywords: Plasmonics
Cell growth
Functional assays
Diffraction field imaging
Publisher: American Chemical Society
Abstract: Functional assay platforms could identify the biophysicalpropertiesof cells and their therapeutic response to drug treatments. Despitetheir strong ability to assess cellular pathways, functional assaysrequire large tissue samples, long-term cell culture, and bulk measurements.Even though such a drawback is still valid, these limitations didnot hinder the interest in these platforms for their capacity to revealdrug susceptibility. Some of the limitations could be overcome withsingle-cell functional assays by identifying subpopulations usingsmall sample volumes. Along this direction, in this article, we developeda high-throughput plasmonic functional assay platform to identifythe growth profile of cells and their therapeutic profile under therapiesusing mass and growth rate statistics of individual cells. Our technologycould determine populations' growth profiles using the growthrate data of multiple single cells of the same population. Evaluatingspectral variations based on the plasmonic diffraction field intensityimages in real time, we could simultaneously monitor the mass changefor the cells within the field of view of a camera with the capacityof > & SIM;500 cells/h scanning rate. Our technology could determinethe therapeutic profile of cells under cancer drugs within few hours,while the classical techniques require days to show reduction in viabilitydue to antitumor effects. The platform could reveal the heterogeneitywithin the therapeutic profile of populations and determine subpopulationsshowing resistance to drug therapies. As a proof-of-principle demonstration,we studied the growth profile of MCF-7 cells and their therapeuticbehavior to standard-of-care drugs that have antitumor effects asshown in the literature, including difluoromethylornithine (DFMO),5-fluorouracil (5-FU), paclitaxel (PTX), and doxorubicin (Dox). Wesuccessfully demonstrated the resistant behavior of an MCF-7 variantthat could survive in the presence of DFMO. More importantly, we couldprecisely identify synergic and antagonistic effects of drug combinationsbased on the order of use in cancer therapy. Rapidly assessing thetherapeutic profile of cancer cells, our plasmonic functional assayplatform could be used to reveal personalized drug therapies for cancerpatients.
URI: https://doi.org/10.1021/acssensors.3c00208
https://hdl.handle.net/11147/13605
ISSN: 2379-3694
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
Plasmonic-Functional.pdf
  Until 2025-01-01
6.96 MBAdobe PDFView/Open    Request a copy
Show full item record



CORE Recommender

Page view(s)

48
checked on Jun 17, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.